Abbott India Final Dividend Record Date on July 25: What It Means for Shareholders?

Abbott India Ltd has set July 25, 2025, as the record date for its final dividend. On May 15, 2025, Abbott India board recommended a final dividend of ₹475 per share. 

Abbott India Ltd said in an exchange filing, “The Board of Directors recommended payment of final dividend of Rs. 475/- per equity share of Rs.10/- each for the financial year ended March 31, 2025, subject to approval of the Shareholders at the ensuing Eighty-first Annual General Meeting of the Company. The Company has fixed Friday, July 25, 2025, as the Record Date for determining the entitlement of Members to the final dividend for the financial year ended March 31, 2025. The dividend, if approved by the Shareholders, will be paid on or after Monday, August 18, 2025.”

What Does Abbott India Dividend Record Date Mean for Shareholders?

As Abbott India Ltd has set July 25 as the record date for its final dividend, meaning that July 24 marks the last day to buy Abbott India shares to become eligible for the final dividend. Further, any shares bought on or after July 25 (record date), won't be eligible for the final dividend due to the T+1 settlement rule.

Also Read: Upcoming Dividends in July 2025: Nestle India, Biocon, BHEL, TCS, Abbott India & More

Abbott India FY25 Earnings Highlights

For the financial year ended March 31, 2025, the Company reported Revenue from Operations of ₹6,409.15 crores, marking a 9.6% increase over the previous year’s ₹5,848.91 crores. Profit Before Tax stood at ₹1,886.95 crores, reflecting a robust year-on-year growth of 16.6%.

This performance was underpinned by a strategic emphasis on innovation and brand enhancement, which significantly accelerated momentum across the product portfolio. Notable launches during FY 2024–25 included Vonefi in June 2024, Digeraft Tablet in September 2024, and Digene On The Go in March 2025—each contributing meaningfully to portfolio diversification and consumer engagement.

Looking forward, the Company maintained its focus on addressing unmet medical needs and expanding its gastrointestinal (GI) portfolio through differentiated, patient-centric innovations. A key strategic priority remained the integration of a sustainable and profitable hybrid promotional model for legacy consumer-facing brands such as Cremaffin and Digene. This approach was set to be driven by enhanced consumer outreach and ethically aligned promotion, especially within the laxatives and antacids segments.

For investors tracking Abbott India performance, holding shares through a Demat account ensures secure and seamless access to corporate actions like dividends and earnings updates.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in securities market are subject to market risks, read all the related documents carefully before investing.